绥美凯（Inbec）说明书

The ingredients are: abacavir (ABC) + lamivudine (3TC) + DTG. The antiviral effect of Inbec is similar to that of tenofovir, but it has less damage to mitochondria, thus reducing adverse reactions such as fat consumption, pancreatitis, neuritis, and lactic acidosis. Today we will take a look at the Inbec manual.

Generic name: Doptabalamid tablets

Product name: Suimeikai

All names: Suimeike, Dotiabalamid tablets, TRIUMEQ, Inbec

Indications: Inbec is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40 kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir. 

Adverse reactions: nausea (12%), insomnia (7%), dizziness (6%) and headache (6%). Patients with abacavir hypersensitivity often experience nausea, vomiting, diarrhea, fever, drowsiness, rash and other symptoms when using this product. If patients experience these symptoms, they should be carefully evaluated for the presence of such a hypersensitivity reaction. In very rare cases of Inbec, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis may occur, and abacavir hypersensitivity cannot be excluded. In such cases, abacavir-containing medicinal products should be permanently discontinued. In individual patients, hypersensitivity reactions, including rash and severe hepatic effects, may occur.

How to take: 1. Inbec should be taken under the guidance of a physician with experience in treating HIV infection. Adults and adolescents (weighing at least 40 kg): For adults and adolescents, the recommended dose is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given as this product is a fixed-dose tablet and the dose cannot be reduced. 

2 Inbec is a fixed-dose tablet and cannot be used in patients who require dose adjustment. If discontinuation or dose adjustment of one of the active ingredients is necessary, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these drugs. 

3. If the patient misses a dose of Inbec and there are more than 4 hours before the next dose, the patient should take this product as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. 

4. Pediatric use: The safety and effectiveness of Inbec in children under 12 years of age have not been determined. No data yet. 

5. Medication in elderly patients: In patients aged 65 and above, there are limited data on the use of dolutegravir, abacavir and lamivudine. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when using Suimika in this age group.

The above is the content of the manual, I hope it can help you!